# Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

> **NCT00137865** · PHASE1 · TERMINATED · sponsor: **EGEN, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **GENETIC:** EGEN-001 (phIL-12-005/PPC)

## Key facts

- **NCT ID:** NCT00137865
- **Lead sponsor:** EGEN, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Sponsor decided to terminate the study early so they could begin a second dose-escalation study of EGEN-001 in combination with standard chemotherapy.
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137865, "Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00137865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*